Naturally occurring stilbenoid tsg reverses non-alcoholic fatty liver diseases via gut-liver axis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Lin, Pei ^a   Lu, Jianmei ^a   Wang, Yanfang ^a   Gu, Wen ^a   Yu, Jie ^a   Zhao, Ronghua ^a  

^a YUNNAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,5,4' TETRAHYDROXY STILBENE 2 O BETA GLUCOSIDE; ENDOTOXIN; FATTY ACID BINDING PROTEIN; FATTY ACID TRANSPORTER 4; GLUCOSAMINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OCCLUDIN; PROTEIN ZO1; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; 2,3,5,4'-TETRAHYDROXYSTILBENE-2-O-GLUCOSIDE; GLUCOSIDE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DIGESTIVE SYSTEM; DISEASE SEVERITY; DOWN REGULATION; DRUG MEGADOSE; FAT CONTENT; FEMALE; GUT LIVER AXIS; IN VIVO STUDY; INTESTINE FLORA; INTESTINE MUCOSA; LIPID STORAGE; LIVER PROTECTION; LOW DRUG DOSE; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; SEX DIFFERENCE; UPREGULATION; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FLOW CYTOMETRY; INFLAMMATION; LIPID DIET; LIVER; MICROBIOLOGY; MICROFLORA; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; DIET, HIGH-FAT; FLOW CYTOMETRY; GLUCOSIDES; INFLAMMATION; INTESTINAL MUCOSA; LIVER; MALE; MICROBIOTA; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STILBENES;

EID: 84949024546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140346     Document Type: Article

References (39)

1. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62. PMID: 15660501
2. Wattacheril J, Chalasani N. Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology 2012; 56:1580-1584. doi: 10.1002/hep.26031 PMID: 23038652
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419. PMID: 10348825
4. Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat. Clin. Pract. Gastroenterol 2013; 10: 637-644
5. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liveraxis in hepatic disease. Hepatology 2014; 59: 328-339. doi: 10.1002/hep.26494 PMID: 23703735
6. Machado MV, Cortez-Pinto H. Gutmicrobiotaand nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 440-449. PMID: 22700625
7. Miura K, Seki E, Ohnishi H, Brenner DA. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2011.
8. Broering R, Lu M, Schlaak JF. Role of Toll-like receptors in liver health and disease. Clin Sci 2011; 121: 415-426. doi: 10.1042/CS20110065 PMID: 21797822
9. Heinrichsdorff J, Olefsky JM. Fetuin-A: the missing link in lipid-induced inflammation. Nat Med 2012; 18(8): 1182-1183. doi: 10.1038/nm.2869 PMID: 22869185
10. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in My D88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-421. PMID: 15034566
11. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology 2008; 48: 322-335. doi: 10.1002/hep.22306 PMID: 18506843
12. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr2007; 86:285-300. PMID: 17684197
13. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100:1082-1090. PMID: 15842582
14. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of piogli-tazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297-2307. PMID: 17135584
15. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-1685. doi: 10.1056/NEJMoa0907929 PMID: 20427778
16. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023. doi: 10.1002/hep.25762 PMID: 22488764
17. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342. PMID: 17086191
18. Ito-Nagahata T, Kurihara C, Hasebe M, Ishii A, Yamashita K, Iwabuchi M, et al. Stilbene analogs of resveratrol improve insulin resistance through activation of AMPK. Biosci Biotechnol Biochem2013; 77: 1229-1235. PMID: 23748787
19. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012; 7: e42529. doi: 10.1371/journal.pone.0042529 PMID: 22880019
20. Wang WG, He YR, Lin P, Li YF, Sun RF, Gu W, et al. In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism. J Ethnopharmacol 2014; 153: 763-770. doi: 10.1016/j.jep.2014.03.042 PMID: 24680992
21. Zhang S, Wang W, Wang J. Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo. Acta Pharmacol Sin 2009; 30:1479-1487. doi: 10.1038/aps.2009.144 PMID: 19890356
22. Sun F, Zhang L, Zhang R, Li L. Tetrahydroxystilbene glucoside protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Eur J Pharmacol 2011; 660: 283-290. doi: 10.1016/j. ejphar.2011.03.046 PMID: 21497157
23. Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol 2014; 49: 785-798. doi: 10.1007/s00535-014-0953-z PMID: 24652102
24. Zhong L, Fan JG, Wang GL, Wu WQ, Jiang JM, Shi Q. The establishment of nonalcoholic steatohepatitis (NASH) animal model. J Chin Prac Med 2000; 2: 3-6.
25. Fan JG, Zhong L, Xu ZJ, Tia LY, Ding XD, Li MS, et al. Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 2003; 9: 2045-2049. PMID: 12970903
26. Ashburne M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. Nat Genet 2000; 25:25-29. PMID: 10802651
27. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIMEallows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-336. doi: 10.1038/nmeth.f.303 PMID: 20383131
28. Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011; 27: 2957-2963. doi: 10.1093/bioinformatics/btr507 PMID: 21903629
29. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5.
30. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809. doi: 10.1038/nri2653 PMID: 19855405
31. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013; 70: 631-659. doi: 10.1007/s00018-012-1070-x PMID: 22782113
32. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discovery 2008; 7: 489-503. doi: 10.1038/nrd2589 PMID: 18511927
33. Stahl A, Gimeno RE, Tartaglia LA, Lodish HF. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab2001; 12: 266-273. PMID: 11445444
34. Feng A, Chen D. The expression and the significance of L-FABP and FATP4 in the development of nonalcoholic fatty liver disease in rats. Chin J Hepatol 2005; 13: 776-779.
35. Yu J, Lin P, Lu JM, Wang WG, Gu W, Zhao RH. Effects of stilbene glucoside on lipid synthesis, decomposition and transport in steatotic L-02 hepatocytes. Chin Pharm J 2014; 23: 2077-2082.
36. Dai X, Lv Z, Wang B, Zhou L. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepato-Gastroenterology 2013; 61:136-140.
37. Rivera CA, Adegboyega P, Rooijen NV, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47:571-579. PMID: 17644211
38. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 51: 212-223. doi: 10.1016/j.jhep.2009.03.008 PMID: 19447517
39. Tilg H, Moschen AR. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J Hepatol 2011; 55: 960-962. doi: 10.1016/j.jhep.2011.04.007 PMID: 21742000